AngioDynamics Appoints Eric Honroth

AngioDynamics announced a leadership change on October 8, 2026. AngioDynamics announced that Eric Honroth, who most recently served as Global President, Life Science at Getinge, will become President and CEO on November 2, 2026, succeeding Jim Clemmer, who is retiring after ten years in the role.

What changed

Eric Honroth was named President and Chief Executive Officer. Jim Clemmer, who is retiring after ten years as President and Chief Executive Officer, will depart the Board on November 2, 2026, and will remain in a consulting capacity to ensure a smooth transition.

Leader: Eric Honroth
Role: President and Chief Executive Officer
Effective: November 2, 2026
Announcement date: October 8, 2026

Leadership background

Honroth has more than 20 years of medical device and life sciences leadership experience, with earlier senior leadership roles at Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific. Most recently he served as Global President, Life Science at Getinge, and previously led Getinge’s $1.2 billion North American business.

The mandate

AngioDynamics said its Board-led search prioritized a leader with medical technology experience to build on the company’s Med Tech momentum and drive sustainable revenue growth, margin expansion, and long-term shareholder value.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Primary source: AngioDynamics leadership announcement.